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tioning regimens (reduced-intensity conditioning and nonmyeloablative) in patients with non-Hodgkin lym-
phoma who relapsed after autologous hematopoietic stem cell transplantation. Nonrelapse mortality,
lymphoma progression/relapse, progression-free survival (PFS), and overall survival were analyzed in 263
patients with non-Hodgkin lymphoma. All 263 patients had relapsed after a previous autologous hematopoi-
etic stem cell transplantation and then had undergone allogeneic hematopoietic stem cell transplantation
from a related (n5 26) or unrelated (n5 237) donor after reduced-intensity conditioning (n5 128) or non-
myeloablative (n 5 135) and were reported to the Center for International Blood and Marrow Transplant
Research between 1996 and 2006. The median follow-up of survivors was 68 months (range, 3-111 months).
Three-year nonrelapse mortality was 44% (95% confidence interval [CI], 37%-50%). Lymphoma progression/
relapse at 3 years was 35% (95% CI, 29%-41%). Three-year probabilities of PFS and overall survival were 21%
(95%CI, 16%-27%) and 32% (95%CI, 27%-38%), respectively. Superior Karnofsky Performance Score, longer
interval between transplantations, total body irradiation-based conditioning regimen, and lymphoma
remission at transplantation were correlated with improved PFS. Allogeneic hematopoietic stem cell
transplantation after lower-intensity conditioning is associated with significant nonrelapse mortality but
can result in long-term PFS. We describe a quantitative risk model based on pretransplantation risk factors
to identify those patients likely to benefit from this approach.
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Autologous hematopoietic stem cell transplanta-
tion (auto-HSCT) is widely used to treat patients
with recurrent or refractory non-Hodgkin lymphoma
(NHL) [1,2]. Unfortunately, relapse is common after
auto-HSCT, and the prognosis for these patients is
poor [3]. Conventional chemotherapy is noncurative
after auto-HSCT failure, and a second auto-HSCT
mostly benefits only a small group of patients who re-
lapse after a long lymphoma-free interval [4,5]. The
results of conventional myeloablative allogeneic
hematopoietic stem cell transplantation (allo-HSCT)
performed in this setting are also poor (5%
progression-free survival [PFS] at 5 years), as reported
previously [6]. In addition, many patients are not can-
didates for myeloablative conditioning because of ad-
vanced age or the presence of comorbidities.
Reduced-intensity conditioning (RIC) and non-
myeloablative conditioning (NST) regimens are in-
creasingly used in patients with NHL. These
lower-intensity conditioning regimens reportedly
have lower nonrelapse mortality (NRM) and can be
used in older patients with comorbidities [7]. Lower-
intensity regimens for allo-HSCT use lower doses of
conditioning chemotherapy and radiation and rely on
an immune-mediated graft-versus-lymphoma (GVL)
effect for disease control. The magnitude of this effect
in the treatment of NHL is unclear [8,9].
Previous studies reporting on RIC or NST allo-
HSCT in patients with NHL who relapsed after
auto-HSCT have included limited numbers of
patients, with variable histologies and variable follow-
up, limiting comparisons [10-14]. To analyze the
wider applicability and effectiveness of this modality,
we analyzed long-term outcomes of lower-intensity
(RIC/NST) allo-HSCT in patients with relapsed B
cell NHL (B-NHL) after a previous auto-HSCTusing
data from the Center for International Blood andMar-
row Transplant Research (CIBMTR). To date, this
represents the largest study of patients with NHL
treated with lower-intensity conditioning allo-HSCT
after auto-HSCT failure.SUBJECTS AND METHODS
Data Sources
The CIBMTR is a research affiliation of the Inter-
national Bone Marrow Transplant Registry (IBMTR)
and the National Marrow Donor Program (NMDP)
established in 2004. It comprises a voluntary working
group of more than 450 transplantation centers world-
wide that contribute detailed data on consecutive allo-
and auto-HSCTs to a Statistical Center at theMedical
College of Wisconsin in Milwaukee and the NMDP
Coordinating Center in Minneapolis. Participatingcenters are required to report all HSCTs consecu-
tively, with compliance monitored by onsite audits.
Patients are followed longitudinally, with yearly
follow-up. Computerized checks for discrepancies,
physicians’ reviews of submitted data, and onsite audits
of participating centers ensure data quality. Observa-
tional studies conducted by the CIBMTR are per-
formed in compliance with the Privacy Rule
(HIPAA) as a public health authority and in compli-
ance with all applicable federal regulations pertaining
to the protection of human research participants, as
determined by continuous review of the Institutional
Review Boards of the NMDP and theMedical College
of Wisconsin since 1985.
Subjects
Outcomes of 263 adult patients (aged .21 years)
with B-NHL who relapsed after auto-HSCT and
then received a lower-intensity conditioning regimen
followed by allo-HSCT between 1996 and 2006 were
analyzed. Follicular, diffuse large B cell (DLBCL),
and mantle cell lymphoma histologies were included.
Recipients of planned tandem auto-/allo-HSCT and
those in first complete response (CR) at the time of
allo-HSCT were excluded. Donors were an HLA-
matched sibling for 26 recipients and an HLA-
matched unrelated donor (URD) for 237 recipients.
Only a limited number of patients who relapse
after auto-HSCT subsequently undergo allo-HSCT.
In the period from 1990 to 2006, a total of 6,395
with relapsed B-NHL after auto-HSCT registered
with the CIBMTR, 373 of whom (5.8%) underwent
subsequent allo-HSCT after an RIC/NST condition-
ing regimen. Our cohort is a subset of those patients
for whom comprehensive data were available, with
high-level reporting and complete case report forms.
We confirmed that the global cohort and the study
subset had similar outcomes.
Definitions
Lower-intensity conditioning regimens were cate-
gorized as RIC or NST using established consensus
criteria [15]. Previously established validated criteria
for categorizing the degree of HLA matching were
used [16]. Well-matched cases had either no identified
HLA mismatching and informative data at four loci or
allele matching at HLA-A, -B, and -DRB1 (6/6).
Endpoints
Primary outcomes were NRM, relapse/progres-
sion, PFS, and survival. NRM was defined as death
from any cause during the first 28 days after transplan-
tation or death without evidence of lymphoma
progression/relapse. Progression was defined as an in-
crease of $25% in the sites of lymphoma or develop-
ment of new sites of lymphoma. Relapse was defined
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Autologous Transplantion Failureas recurrence of lymphoma after a CR. For PFS,
a patient was considered a treatment failure at the
time of relapse/progression or death from any cause.
Patients alive without evidence of disease relapse or
progression were censored at last follow-up, and the
PFS event was summarized by a survival curve. The
OS interval variable was defined as the interval from
the date of transplantation to the date of death or last
contact and summarized by a survival curve. Other
outcomes analyzed included acute and chronic graft-
versus-host disease (GVHD) and cause of death. Acute
GVHD was defined and graded based on the pattern
and severity of organ involvement using established
criteria [17]. Chronic GVHDwas defined as the devel-
opment of any chronic GVHD based on clinical
criteria. Both of these events were summarized by
the corresponding cumulative incidence estimate,
with death without development of GVHD as the
competing risk.Statistical Analyses
Probabilities of PFS and OS were calculated using
the Kaplan-Meier product limit estimate. Probabilities
of NRM, lymphoma progression/relapse, and acute
and chronic GVHD were calculated using cumulative
incidence curves to accommodate competing risks
[18,19]. Associations among subject-, disease-, and
transplantation-related factors and outcomes of inter-
est were evaluated usingmultivariate Cox proportional
hazards regression. A stepwise forward selection mul-
tivariate model was built to identify covariates that
influenced outcomes. Covariates with a P value\.05
were considered significant. The proportionality as-
sumption for Cox regression was tested by adding
a time-dependent covariate for each risk factor and
each outcome [20]. All variables met the proportional
hazards assumption. Results are expressed as relative
risk (RR) or the relative rate of occurrence of the event.
The following variables were considered in multi-
variate analyses: age at allo-HSCT, sex, Karnofsky
Performance Score (KPS) at allo-HSCT, time from
diagnosis to auto-HSCT, time between auto-HSCT
and allo-HSCT, NHL histology, disease status and
sensitivity to chemotherapy at allo-HSCT, condition-
ing regimen intensity (RIC vs NST), donor type
(HLA-identical related vs HLA well-matched URD
vs HLA partially matched URD), donor–recipient
sex match (female donor and male recipient versus all
other combinations), donor–recipient cytomegalovi-
rus (CMV) state (donor and recipient CMV-
seronegative vs all other combinations), graft source
(bone marrow vs peripheral blood), year of allo-
HSCT (1996-2003 vs 2004-2006) and type of
GVHD prophylaxis. Information on the interval
from auto-HSCT to relapse was not available in all pa-
tients; thus, the interval between auto-HSCT and allo-HSCTwas used as a surrogate variable, combining the
interval from auto-HSCT to relapse and the interval
from such relapse to allo-HSCT.RESULTS
Patient- and Transplantation-Related Variables
Patient-, disease-, and transplantation-related
characteristics are presented in Table 1. A total of
263 patients from 69 centers underwent allo-HSCT
for NHL with lower-intensity conditioning after re-
lapsing after a previous auto-HSCT. The median pa-
tient age at allo-HSCT was 52 years (range, 23-70
years). Eighty-nine patients (34%) had a KPS\90 at
the time of allo-HSCT.
A total of 147 patients (56%) had DLBCL or fol-
licular large cell NHL, 72 (27%) had mantle cell lym-
phoma, and 44 (17%) had follicular lymphoma. In 57
patients, DLBCL was reportedly the result of histo-
logical transformation from a lower-grade lymphoma.
The median interval from diagnosis to auto-HSCT
was 19 months (range, 2-278 months). Eighty-five
patients (33%) underwent auto-HSCT within 1 year
after diagnosis. The median interval between auto-
HSCT and allo-HSCT was 25 months (range, 4-159
months). Fifty-two patients (20%) underwent allo-
HSCT within 1 year after auto-HSCT, 80 patients
(30%) did so between 1 and 2 years after auto-
HSCT, and 131 (50%) did so more than 2 years after
auto-HSCT. Only 67 patients (27%) were in second
or greater CR (CR21) at the time of allo-HSCT. A to-
tal of 169 patients (63%) were considered to have
chemotherapy-sensitive disease at allo-HSCT.
Conditioning regimens were classified as RIC in
128 patients (49%) and NST in 135 patients (51%).
Sixty-six patients (25%) received total body radiation
(TBI) of 2 Gy, 65 patients (25%) received lower-
dose melphalan (\150 mg/m2), and 62 patients
(24%) received fludarabine and cyclophosphamide
regimens. Three-fourths of the patients received ritux-
imab at some point before allo-HSCT. A bonemarrow
graft source was used in 21%. One hundred forty-one
patients (54%) underwent allo-HSCT between 2004
and 2006. Seventeen (6%) received donor lymphocyte
infusion (DLI) for relapse or failure to achieve CR
after allo-HSCT. Median follow-up of survivors was
68 months (range, 3-111 months).
Outcomes
Patient outcomes are summarized in Table 2. One
hundred ninety-four of the 263 patients died (74%).
Twenty-three patients (9%) were alive with lym-
phoma, and 46 (18%) were alive and lymphoma-free
without relapse at last follow-up. The 100-day mortal-
ity rate was 30% (95% confidence interval [CI],
25%-36%).NRMrates were 39% (95%CI, 33%-45%)
Table 1. Patient-, Disease- and Transplantation-Related
Characteristics
Variable
Number of patients 263
Age at allo-HSCT, median (range), years 52 (23-70)
Age at allo-HSCT, years, n (%)
21-30 14 (5)
31-40 34 (13)
41-50 71 (27)
51-60 107 (41)
$61 37 (14)
Male sex, n (%) 168 (64)
KPS <90 at allo-HSCT, n (%) 89 (34)
Histology at allo-HSCT, n (%)
Follicular large/DLBCL 147 (56)
Follicular 44 (17)
Mantle cell 72 (27)
Histological transformation after diagnosis, n (%) 57 (22)
Time from diagnosis to first auto-HSCT, months, median
(range)
19 (2-278)
Time from auto- to allo-HSCT, months, median (range) 25 (4-159)
Time from auto- to allo-HSCT, months, n (%)
<12 52 (20)
12-24 80 (30)
>24 131 (50)
Disease status at allo-HSCT, n (%)
CR2+ 67 (27)
PIF (never in CR) 22 (9)
Relapse-sensitive 90 (36)
Relapse-resistant 58 (23)
Relapse unknown/untreated 14 (6)
Chemosensitivity disease at allo-HSCT, n (%)
Sensitive 159 (63)
Others 104 (37)
Donor type, n (%)
Related 26 (10)
Unrelated 237 (90)
Donor-recipient sex match, n (%)
M-M 112 (43)
M-F 54 (21)
F-M 56 (21)
F-F 41 (16)
Donor/recipient CMV status, n (%)
+/+ 50 (19)
+/2 23 (9)
2/+ 90 (34)
2/2 87 (33)
Not tested/inconclusive 11 (4)
Conditioning regimen for allo-HSCT, n (%)
Low-dose TBI-based (<500 cGy) 9 (3)
Melphalan dose #150 mg/m2 65 (25)
Busulfan dose #9 mg/kg 54 (21)
TBI dose 200 cGy 66 (25)
Fludarabine + cyclophosphamide 62 (24)
Fludarabine only 7 (3)
Conditioning regimen at second transplantation, n (%)
Reduced-intensity 128 (49)
Nonmyeloablative 135 (51)
Rituximab before allo-HSCT, n (%) 195 (74)
Type of donor, n (%)
Well matched 150 (57)
Partially matched 69 (26)
Mismatched 12 (5)
Unrelated, matching unknown 6 (2)
Related 26 (10)
Graft source, n (%)
Bone marrow 56 (21)
Peripheral blood 207 (79)
Year of allo-HSCT, n (%)
1996-1997 2 (1)
1998-1999 8 (3)
2000-2001 41 (16)
2002-2003 71 (27)
(Continued )
Table 1. (Continued )
Variable
2004-2006 141 (54)
GVHD prophylaxis at allo-HSCT, n (%)
Methotrexate + cyclosporine ± other 35 (13)
Cyclosporine ± other 96 (37)
Methotrexate + tacrolimus ± other 72 (27)
Tacrolimus ± other 51 (19)
T cell depletion ± other 4 (2)
Other/unspecified 5 (2)
Donor lymphocyte infusion after allo-HSCT, n (%)a 17 (6)
Follow-up of survivors, months, median (range) 68 (3-111)
aFive patients (29%) are alive, and 12 (71%) are dead. Sixteen patients
(95%) relapsed/progressed after second transplantation. Completeness
index follow-up, 90%.
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(95% CI, 40%-53%) at 5 years after allo-HSCT.
The incidence of lymphoma progression/relapse
was 31% (95% CI, 25%-36%) at 1 year, 35%
(95% CI, 29%-41%) at 3 years, and 36% (95% CI,
30%-42%) at 5 years after allo-HSCT. Figure 1A
shows cumulative incidences of NRM and lymphoma
progression/relapse.
Figure 1B shows actuarial probabilities of PFS and
OS. PFS rates were 30% (95% CI, 25%-36%) at 1
year, 21% (95% CI, 16%-27%) at 3 years, and 17%
(95% CI, 13%-22%) at 5 years after allo-HSCT.
Corresponding OS rates were 44% (95% CI, 38%-
50%), 32% (95% CI, 27%-38%), and 27% (95% CI,
21%-32%).Table 2. Univariate Outcome Probabilities
Outcome Event Probability (95% CI)a
30-day mortality 10 (7-15)
100-day mortality 30 (25-36)
Absolute neutrophil count >0.5  109/L
28 days 91 (87-95)
100 days 95 (92-97)
Acute GVHD at 100 days, grades II-IV 39 (34-45)
Chronic GVHD
1 year 37 (31-43)
3 years 40 (34-46)
5 years 40 (34-46)
NRM
1 year 39 (33-45)
3 years 44 (37-50)
5 years 47 (40-53)
Progression/relapse
1 year 31 (25-36)
3 years 35 (29-41)
5 years 36 (30-42)
PFS
1 year 30 (25-36)
3 years 21 (16-27)
5 years 17 (13-22)
OS
1 year 44 (38-50)
3 years 32 (27-38)
5 years 27 (21-32)
aProbabilities of absolute neutrophil count >0.5  109/L, acute and
chronic GVHD, NRM, and progression/relapse were calculated using
the cumulative incidence estimate; 100-day mortality, PFS, and OS
were calculated using the Kaplan-Meier product limit estimate.
Figure 1. (A) Cumulative incidence of NRM and disease progression after RIC/NST in patients who relapsed after auto-HSCT for NHL. (B) Proba-
bilities of PFS and OS after RIC/NST in patients who relapsed after auto-HSCT for NHL.
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Autologous Transplantion FailureThe incidence of grade II to IV acute GVHD
within 100 days of transplantation was 39% (95%
CI, 34%-45%). The incidence of chronic GVHD
was 37% (95% CI, 31%-43%) at 1 year and 40%
(95% CI, 34%-46%) at 5 years after allo-HSCT.
PFS was not correlated with histological type of
NHL (Figure 2), except for lower PFS (but not lower
OS) in patients with transformed large cell lymphoma.
Seventeen patients received DLI after allo-HSCT
for lymphoma progression/relapse. Survival after DLI
was low: 12% (95% CI, 2%-31%) at 1 year, 6% (95%
CI, 0-24%) at 3 years, and 6% (95% CI, 0-24%) at 5
years. Causes of death were lymphoma-relapse/
progression in 50 patients (26%), infection in 33
(17%), organ failure in 32 (16%), and acute or chronic
GVHD in 23 (12%) (Table 3).Multivariate Analyses
NRM
KPS was significantly correlated with NRM. Pa-
tients with a KPS\90 had an increased risk of NRMFigure 2. Probability of PFS after RIC/NST in patients who relapsed after(RR, 2.57; 95% CI, 1.57-3.25; P \ .001). Figure 3
illustrates the probability of NRM based on KPS.
Lymphoma progression/relapse
The interval between auto-HSCT and allo-HSCT
was significantly correlated with the risk of lymphoma
progression/relapse. Recipients of allo-HSCT within
2 years after auto-HSCT were at greater risk for
progression/relapse (RR, 2.09; 95% CI, 1.37-3.18;
P 5 .001) (Figure 4).
PFS and treatment failure
Table 4 presents the results of multivariate analysis
of PFS. Patients with a KPS\90 had nearly a two-fold
increased risk of treatment failure and lower PFS,
compared with patients with a higher KPS (RR, 1.78;
95% CI, 1.33-2.40; P \ .001). Those undergoing
allo-HSCT within 2 years after previous auto-HSCT
had a lower PFS and higher risk of treatment failure
(RR, 1.49; 95% CI, 1.13-1.96; P 5 .004). Recipients
of non–TBI-containing conditioning regimens had
a lower PFS (RR of treatment failure, 1.66; 95% CI,
1.20-2.29; P5 .002). Patients who had never achievedauto-HSCT for NHL, according to histology at the time of RIC/NST.
Table 3. Causes of Death (n 5 194 Patients Evaluated)
Cause of Death n (%)
Primary disease 50 (26)
GVHD 23 (12)
Pulmonary syndrome 11 (6)
Infection 33 (17)
Organ failure 32 (16)
Hemorrhage 5 (3)
New malignancy 2 (1)
Vascular 2 (1)
Unknown 36 (19)
1260 Biol Blood Marrow Transplant 18:1255-1264, 2012C. O. Freytes et al.CR (ie, primary induction failure [PIF]) had lower PFS
(RR of treatment failure, 1.89; 95%CI, 1.12-3.18; P5
.017). Figure 5 shows the probability of PFS according
to risk factors. Figure 6 shows PFS after allo-HSCT
by individual conditioning regimens. The type of
conditioning regimen, RIC versus NST, did not im-
pact PFS.
GVHD
Patients with KPS \90, those receiving a TBI-
based conditioning regimen, and those receiving a graft
from a female donor were at increased risk of develop-
ing grade II to IV acute GVHD. The sole variable cor-
related with chronic GVHD was the graft source;
recipients of peripheral blood cell grafts were at
greater risk than recipients of bone marrow grafts
(RR, 2.45; 95% CI, 1.33-4.48; P 5 .004). Patients
with grade II to IV acute GVHDwere less likely to de-
velop lymphoma progression/relapse (RR, 0.55; 95%
CI, 0.34-0.90; P 5 .0166) in univariate analysis, but
this difference was not statistically significant in the
multivariate model. Chronic GVHD had no impact
on the probability of lymphoma relapse/progression
(RR, 0.71; 95% CI, 0.37-1.34; P 5 .2869).
OS
OS was significantly correlated with KPS. Patients
with a KPS of\ 90 had a greater risk of death (RR,
1.92; 95% CI, 1.43-2.56; P\ .001).Figure 3. Probability of NRM after RIC/NSTaccording to KRisk model
Based on the significant pretransplantation vari-
ables identified in the multivariate model, we devel-
oped a risk scoring system, outlined in Table 5.
Patients with all four adverse risk factors (KPS\90,
never in CR, non–TBI-based conditioning, and #24
months between auto-HSCT and allo-HSCT) had
an 8.32-fold greater risk of death or relapse compared
with patients with no risk factors. Similarly, patients
with three risk factors (KPS \90, never in CR, and
non–TBI-based conditioning) had a 5.58-fold greater
risk of death or relapse, and those with two risk factors
(KPS\90 and never in CR) had a 3.36-fold greater
risk of death or relapse.DISCUSSION
The aims of the present study were to define out-
comes after allo-HSCT using lower-intensity condi-
tioning regimens in patients with B-NHL who
relapsed after auto-HSCT and to identify correlations
between subject-, disease-, and treatment-related vari-
ables and outcomes. This study involves a large cohort
of patients from multiple centers with long follow-up,
thereby providing a perspective on the feasibility and
effectiveness of this treatment strategy.
Despite the lower intensity of the conditioning
regimens in our cohort, 3-year NRM was high at
44% (95% CI, 38%-46%). In multivariate analysis,
KPS was the sole predictor of NRM; patients with
a KPS\90 had a two-fold greater NRM compared
with patients with a KPS$90. The NRM in this study
is higher than previously reported values. In a study by
Branson et al [21] using HLA-identical sibling donors,
the 14-month NRM was 20%. Martino et al [7] re-
ported a 24% NRM (95% CI, 15%-41%) at 1 year
with HLA-identical sibling donors and Escalon et al
[22] reported a 5%NRM in patients with chemosensi-
tive lymphoma who received a transplantation from an
HLA-identical related donor. Baron et al [23] reportedPS in patients who relapsed after auto-HSCT for NHL.
Figure 4. Probability of relapse after RIC/NST in patients who relapsed after auto-HSCT for NHL, according to the time interval between
transplantations.
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Autologous Transplantion Failurea 28% NRM at 3 years after allo-HSCT from URDs.
A recently published study by the European Group for
Blood andMarrow Transplantation (EBMT) reported
a 3-year NRM of 28.2% [24]. It is likely that differ-
ences in NRM between studies reflect differences in
subject selection, proportion of unrelated donors,
and width of CIs. Approximately 40% of the patients
in our study had aKPS\90.Moreover, 90%of our pa-
tients received a URD transplantation. Only 60% of
the URD transplantations were well matched, lower
than the proportions of well-matched URDs in other
studies [22,23]. Another significant difference is that
our study cohort was almost a decade older than the
patients in most previous studies.
The risk for lymphoma progression/relapse was
31% (95% CI, 25%-36%) at 1 year and increased to
36% (95% CI, 30%-42%) at 5 years. These values
are similar to those reported in previous studies
[23,25]. The major risk factor correlated with risk of
lymphoma progression/relapse was a shorter interval
between auto-HSCT and allo-HSCT, which is likelyTable 4. Multivariate Analysis for PFS
Variable n
RR of Relapse/Progression
or Death (95% CI) P value
KPS
$90 138 1.00
<90 119 1.78 (1.33-2.40) <.001
Time from auto-HSCT to
allo-HSCT
>24 months 128 1.00
#24 months 129 1.49 (1.13-1.96) .004
Conditioning regimen for
allo-HSCT
TBI-based 73 1.00
Non–TBI-based 184 1.66 (1.20-2.29) .002
Disease status at allo-HSCT .043
CR2+ 67 1.00
Relapse 156 1.26 (0.90-1.75) .177
PIF 22 1.89 (1.12-3.18) .017
Unknown 12 0.75 (0.37-1.51) .418a surrogate for a short time to relapse after auto-
HSCT. In multivariate analyses, higher KPS, longer
interval between auto-HSCT and allo-HSCT, use of
TBI, and more favorable disease status at the time of
transplantation were correlated with superior PFS.
As in previous studies, disease status at the time of
allo-HSCT was correlated with PFS. Patients with
PIF (who had never achieved previous CR) were at
greatest risk for treatment failure [7,23,26]. In
previous studies, these patients were excluded or had
worse outcomes [22,27]. Interestingly, the use of TBI
in conditioning substantially improved PFS,
consistent with the findings in our previous study of
myeloablative allo-HSCT in this setting [6]. TBI was
also found to decrease the rate of recurrence in a previ-
ous CIBMTR study of follicular lymphomas [8]. The
quantitative risk model that we describe here is predic-
tive of PFS and helps define the risks and benefits of
allo-HSCT in this setting in practice.
Most previous studies had limited statistical power
to detect differences in outcomes among lymphoma
subtypes. Survival was similar in patients with
DLBCL, follicular cell lymphoma, and mantle cell
lymphoma in the present study. Although PFS was
shorter in patients with histological transformation
of follicular lymphoma, this did not translate into
shorter OS.
The use of lower-intensity allo-HSCT is predi-
cated on a GVL effect. Consistently detecting
a GVL effect is difficult in this setting, however [8,9].
In the present study, patients with grade II-IV acute
GVHDwere less likely to develop lymphoma progres-
sion/relapse, but this effect was not significant in mul-
tivariate analysis. In a small study, Mohty et al [12]
reported a correlation between acute GVHD and lym-
phoma relapse. Others have reported a correlation be-
tween chronic GVHD lymphoma progression/
relapse, whereas the EBMT study found no beneficial
effect of either acute or chronic GVHD [23-25]. In
Figure 5. Probability of PFS after RIC/NST in patients who relapsed after auto-HSCT for NHL according to KPS, interval between auto-HSCT and
RIC/NST, use of TBI-containing conditioning regimen, and disease status at the time of RIC/NST.
1262 Biol Blood Marrow Transplant 18:1255-1264, 2012C. O. Freytes et al.aggregate, these data do not support the presence of
a strong, consistent GVL effect in this population of
patients with advanced relapsed NHL.
The present study has several limitations. The in-
terval between auto-HSCT and relapse and the time to
allo-HSCT after relapse are relevant disease-related
variables that were not available to us. Instead, we
used the interval between auto-HSCT and allo-
HSCT as a surrogate incorporating both time inter-
vals. Furthermore, our study population did not
include all patients who relapsed after auto-HSCT
and were eligible for RIC/NST allo-HSCT. In fact,
only a minority of patients who relapse after auto-
HSCT undergo allo-HSCT. The reasons for this are
beyond the scope of our analysis, but might be related
to the failure of salvage therapies for NHL relapse,
early mortality after relapse, ineligibility for allo-
HSCT, or patient/physician choice. Our results areFigure 6. Probability of PFS after RIC/NST in patients who relapsedapplicable only to patients with NHL who undergo
allo-HSCT.
Survival is poor in patients with NHL who relapse
after auto-HSCT [28,29]. Our previous study reported
only a 5% PFS at 5 years after myeloablative allo-
HSCT for patients failing auto-HSCT [6].Myeloabla-
tive conditioning in this setting has been largely
abandoned in favor of lower-intensity conditioning
regimens, as illustrated by the present study and the re-
cent EBMT report [24]. Relapse or progression of
NHL in this cohort of advanced, high-risk patients
who underwent lower-intensity allo-HSCT was 36%
at 5 years, with the vast majority of relapses occurring
within the first year after transplantation. However,
NRM was also high, contributing to the 5-year PFS
of 17% and OS of 27%. More effective and less-toxic
conditioning regimens, as well as posttransplantation
antilymphoma therapy, are needed to improve theseafter auto-HSCT for NHL according to conditioning regimen.
Table 5. Risk Factor Model for PFS
Combination of Variables
RR of Relapse/Progression
or Death (95% CI)
KPS <90 + PIF at allo-HSCT + time between
HSCTs #24 months + non–TBI-based
conditioning
8.32 (4.00-17.33)
KPS <90 + PIF at allo-HSCT + non–TBI-based
conditioning
5.58 (2.82-11.04)
KPS <90 + PIF at allo-HSCT 3.36 (1.84-6.13)
Time between HSCTs #24 months
+ non–TBI-based conditioning
2.47 (1.61-3.81)
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Autologous Transplantion Failureoutcomes, considering that disease progression and
NRM are the most common causes of failure.
Despite these sobering results, our risk model
based on pretransplantation characteristics defines
a subset of patients that can benefit from lower-
intensity allo-HSCT after auto-HSCT failure. Pa-
tients with late relapse, superior KPS, and controlled
disease are especially likely to benefit from this
approach and should be considered for this modality.ACKNOWLEDGMENTS
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